» Articles » PMID: 33240800

Paranasal Sinus Invasion Should Be Classified As T4 Disease in Advanced Nasopharyngeal Carcinoma Patients Receiving Radiotherapy

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Nov 26
PMID 33240800
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, we explored the association between paranasal sinus invasion and prognosis in patients with advanced nasopharyngeal carcinoma (NPC, (T3/T4N0-3M0), and we assessed the possibility of considering paranasal sinus invasion a T category in the 8th edition of the American Joint Committee on Cancer staging system. We enrolled 352 NPC patients who received intensity-modulated radiotherapy between 2008 and 2012. Clinical characteristics and follow-up data were collected. The incidence of paranasal sinus invasion was 36.4% (128 of 352 patients). Multivariate cox regression analysis indicated that paranasal sinus invasion and cervical lymphatic metastasis were independent negative prognostic factors for overall survival (OS, =0.024, =0.012), progression-free survival (PFS, =0.007, =0.007), and distant metastasis-free survival (DMFS, =0.001, =0.000). The gross tumor volume of the nasopharynx was an independent negative prognostic factor for OS (=0.013). Cox regression analysis indicated that there were no significant differences in OS, PFS, DMFS, or local relapse-free survival (LRFS) between NPC patients with T4 stage disease and those with T3 and paranasal sinus invasion (>0.05). The updated T + N staging system slightly improved the prediction of LRFS (0.649, 95% CI: 0.553-0.745) in NPC patients compared to the AJCC system (0.640, 95% CI: 0.545-0.736; =0.023). Paranasal sinus invasion is independently associated with a poor prognosis in NPC patients. Thus, we recommend that the AJCC staging system upgrade paranasal sinus invasion to the T4 classification.

Citing Articles

The Utility of F-FDG-PET-CT Metabolic Parameters in Evaluating the Primary Tumor Aggressiveness and Lymph Node Metastasis of Nasopharyngeal Carcinoma.

Zhang Y, Hu Y, Zhao S, Huang R Clin Med Insights Oncol. 2024; 18:11795549231225419.

PMID: 38322667 PMC: 10845995. DOI: 10.1177/11795549231225419.


The emerging potentials of lncRNA DRAIC in human cancers.

Yao Q, Zhang X, Chen D Front Oncol. 2022; 12:867670.

PMID: 35992823 PMC: 9386314. DOI: 10.3389/fonc.2022.867670.

References
1.
Lee N, Harris J, Garden A, Straube W, Glisson B, Xia P . Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009; 27(22):3684-90. PMC: 2720082. DOI: 10.1200/JCO.2008.19.9109. View

2.
Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

3.
Zhang Y, Peng H, Guo R, Li W, Chen L, Liu X . Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 Cases. J Cancer. 2016; 7(10):1353-9. PMC: 4934044. DOI: 10.7150/jca.15141. View

4.
He Y, Wang Y, Shen L, Zhao Y, Cao P, Lei M . Prognostic value of the distance between the primary tumor and brainstem in the patients with locally advanced nasopharyngeal carcinoma. BMC Cancer. 2016; 16:114. PMC: 4756467. DOI: 10.1186/s12885-016-2148-x. View

5.
He Y, Wang Y, Cao P, Shen L, Zhao Y, Zhang Z . Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Chin J Cancer. 2016; 35(1):96. PMC: 5112747. DOI: 10.1186/s40880-016-0159-2. View